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Essentials
Identifying patients at risk of hospital acquired venous thromboembolism (VTE) is a 
challenge
Caprini, IMPROVE and Padua scores were assessed to predict VTE in medical inpatients 
against advanced age alone
Of 14,660 patients, 1.8% experienced VTE. Area under the ROC curve (AUC) for 
advanced age alone was 0.61
AUC for Caprini, IMPROVE and Padua scores were respectively 0.60, 0.63 and 0.64, no 
better than advanced age













As hospital-acquired venous thromboembolism (VTE) represents a frequent cause of 
preventable deaths in medical inpatients, identifying at risk patients requiring 
thromboprophylaxis is critical. We aimed to externally assess the Caprini, IMPROVE and 
Padua VTE risk scores and to compare their performance to advanced age as a stand-
alone predictor.
Methods
We performed a retrospective analysis of patients prospectively enrolled in the 
PREVENU trial. Patients aged 40-years and older, hospitalised for at least 2-days on a 
medical ward were consecutively enrolled and followed for three months. Critical ill 
patients were not recruited. Patients diagnosed with VTE within 48-hours from admission, 
or receiving full dose anticoagulant treatment or who underwent surgery were excluded. 
All suspected VTE and deaths occurring during the three-month follow-up were 
adjudicated by an independent committee. The three scores were retrospectively 
assessed. Body mass index, needed for the Padua and Caprini scores were missing in 
44% of patients.
Results
Among 14,910 eligible patients, 14,660 were evaluable, of which 1.8% experienced 
symptomatic VTE or sudden unexplained death during the three-month follow-up. The 
area under the receiver operating characteristic curves (AUC) were 0.60 (95%CI 0.57-
0.63), 0.63 (95%CI 0.60-0.66) and 0.64 (95%CI 0.61-0.67) for Caprini, IMPROVE and 
Padua scores, respectively. None of these scores performed significantly better than 
advanced age as a single predictor (AUC 0.61, 95%CI 0.58-0.64). 
Conclusion
In our study, Caprini, IMPROVE and Padua VTE risk scores have poor discriminative 
ability to identify not-critically ill medical inpatients at risk of VTE, and do not perform 
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Introduction
Venous thromboembolism (VTE) is a serious disease, increasing the risk of a life-
threatening pulmonary embolism (PE) or long-term complications. Hospital-acquired VTE 
remains one of the most common etiologies, accounting for more than one third of all 
diagnosed VTE.[1,2] It is estimated that as many as 71% of PE-related deaths occur as a 
consequence of hospitalisation.[3] Due to the challenge of diagnosing PE, this proportion 
may be underestimated. Therefore, a consequent proportion of sudden deaths is 
attributable to unsuspected PE.[4–7]  This highlights the importance of identifying 
hospitalised patients at high risk of VTE who require thromboprophylaxis.
Although criteria for thromboprophylaxis are well established for surgical patients, there is 
no international consensus for medical patients. Most recent recommendations are based 
on risk stratification using clinical prediction rules.[8,9] For this purpose, several risk 
assessment models (RAMs) are proposed. The Padua, Caprini and IMPROVE scores 
are the most widely studied, but they have not been assessed in an implementation 
management study.[10–12] 
Age has been showed to be one of the major determinants of the risk of VTE. Moreover, 
VTE is  highly prevalent among elderly medically ill inpatients.[1,13] Age is the only 
variable constantly identified as an independent predictor in all available RAMs. [10–12] 
Additionally, age is readily available and does not require complex calculation. 
Therefore, we aimed to retrospectively assess whether existing RAMs perform better 




We performed a secondary analysis of a prospectively recruited and followed cohort of 
patients hospitalised for acute medical illnesses, participating in a cluster-randomised 
control trial: The Prevention of Venous Thromboembolism Disease in Emergency 
Departments (PREVENU) study. The methodology was previously described.[14] Briefly, 
the PREVENU study took place in 27 French centres (20 academic centres and seven 
community hospitals) from November 2009 to November 2010. Consecutive patients 
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diagnosed with an acute medical illness requiring hospitalisation were included in the 
PREVENU trial. Patients were excluded if they: i) received anticoagulant treatment at a 
therapeutic dosage before hospitalisation or for a reason other than VTE while 
hospitalised; ii) underwent elective surgery under general anaesthesia; or iii) were 
diagnosed with VTE or discharged within 48 hours following admission. Critically ill 
patients admitted to an intensive care unit (ICU) were not included in the PREVENU trial. 
The randomisation unit was the participating centre. Centers were randomized into the 
control or intervention arm. In the centres allocated to the intervention group, emergency 
physicians received educational support reminding them of the guidelines on 
thromboprophylaxis use for medical inpatients. In the centres allocated to the control 
group, physicians pursued their usual practices. There was no direct patient intervention.
As part of the PREVENU trial, a standardised case report form was completed during the 
hospital admission, collecting information on previous and recent medical history, risk 
factors for VTE, laboratory results, and anticoagulant management. All patients were 
followed for three months. The main outcome was symptomatic VTE, defined as deep 
vein thrombosis (proximal and/or distal), nonfatal and fatal pulmonary embolism or 
unexplained sudden death during the three-month follow- up. All events were adjudicated 
by an independent committee. 
For the present study, the Padua, Caprini and IMPROVE VTE risk scores were 
calculated using data available in the case report. These scores are depicted in Table 1, 
along with information on how each predictor was collected and defined in our study. The 
anticipated length of bed confinement was not collected in the PREVENU study. As a 
substitute, we used the actual hospital length of stay minus one day. Our study focused 
on acutely ill medical patients and did not include critically ill patients admitted to ICU or 
surgical patients. Variables related to ICU admission and surgery included in the 
IMPROVE score and Caprini score were constantly scored as “no” or “zero”. The only 
variable with more than 1% of missing values was body mass index, which could not be 
calculated in 6501 patients (44%), mainly due to missing height values. For this variable, 
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The primary aim of our analysis was to assess the global discriminatory power of the 
RAMs in predicting VTE events, as evaluated by their area under the receiver operating 
characteristics (ROC) curve (AUC), in comparison to advanced age alone, used as a 
continuous variable. 
Secondary aim was to compare the incidence of VTE between low-risk and high-risk 
patients and assess the robustness of our primary results using time-to-event analysis. 
Based on derivation and previous validation studies, patients with a Padua score ≥4, 
Caprini score ≥3, IMPROVE score ≥2 (intermediate and high risk) and IMPROVE score 
≥4 (high risk) were considered at increased risk of VTE. Advanced age was defined when 
reaching 70 years, as defined in the Padua score.
In a first sensitivity analysis, we included only patients not receiving anticoagulant 
treatment during their hospital stay. In a second sensitivity analysis, we defined the 
primary outcome as objectively confirmed VTE only and did not consider unexplained 
sudden death as part of the primary outcome, because reproducibility of adjudication of 
sudden death as fatal PE is poor.[15] In a third sensitivity analysis, we did not consider 
distal DVT as part of the primary outcome, because the clinical relevance and optimal 
management of distal VTE is controversial.[16] In a fourth sensitivity analysis, we 
excluded patients with missing values for BMI.
Statistical analyses
Results were described by their proportion and 95% confidence interval (CI) for 
categorical variables. Mean and standard deviation or median and interquartile range 
were used, as appropriate, to describe continuous variables. The AUC were compared 
using the Delong-Delong tests.[17] When a multiple testing adjustment was required, a 
closed testing procedure based on intersection-union tests was performed. This 
methodology allows an optimal correction of the p-values in the context of multiple 
comparisons of Area Under the ROC curves.[18] This method allows a control of the 
Family Wise Error Rate  at 5%. Calibration plots were depicted and goodness of fit was 
assessed using Hosmer-Lemeshow test. Brier score was used to compare the accuracy 
of probabilistic predictions.[19] To determine the accuracy of the scores to predict VTE, 
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high-risk patients according to the pre-specified thresholds. When sensitivity (Sn) and 
specificity (Sp) were considered with the same importance, the Youden index captures 
the best compromise between both. It was calculated as follows: Sn+Sp-1. Time to event 
(survival) analysis was carried out comparing age to the 3 models to depict event rate 
over time. In order to gauge the magnitude of the difference in the survival analysis, the 
advanced age threshold was adjusted so that the event rate at 90 days in low-risk 
patients based on age would match the event rate in low-risk patients as defined by the 
RAM. To do so, age threshold was set where the risk of experiencing VTE under this age 
threshold corresponded to the risk in the low risk group according to the studied risk 
assessment model. Magnitude of the effect over time would be gauged by the gap 
between the curves in the high-risk group. The type-I error rate was defined at 5%. 
Missing values were imputed using the MissForest package in R, which applies random 
forest theory to impute iteratively missing values. 
Results
Study Population
Among the 20,377 patients enrolled in the PREVENU study, 14,910 were included. The 
main reasons for exclusion were: enrolled during the pre-intervention period without 
follow-up (n=1,686), length of stay of less than 48 hours (n=2,442), anticoagulant 
treatment before admission (n=1,075), or surgery under general anaesthesia (n=523). A 
total of 164 patients (1.1%) were lost in follow-up and 86 (0.6%) had insufficient data to 
calculate the RAMSs, leaving 14,660 patients for analysis (Figure 1). Characteristics of 
the cohort are described in Table 2. Seven thousand eight hundred and ninety-six 
patients (53.9%) did not receive anticoagulant prophylaxis. Main reasons for admission 
were sepsis (21%), acute respiratory failure (12%), stroke or neurological condition with 
motor deficit of a lower limb (10%), acute heart failure (8%) or 
rheumatologic/inflammatory disease (7%).
Main outcome
Overall, 263 patients (1.8%) experienced symptomatic VTE during the three-month 
follow-up, of which eight (3.0%) were definite fatal PE, 127 (48%) were sudden death 
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median time until VTE occurrence was 22 days (interquartile range, 10-46 days). Among 
patients who experienced VTE, 57% received anticoagulant prophylaxis, as opposed to 
46% of patients who did not develop VTE, p<0.001. 
Primary analysis: Performances of risk assessment models
ROC curves of the evaluated RAMs are depicted in Figure 2. The AUC for predicting VTE 
was 0.61 (95% CI 0.58-0.64) for advanced age as a single predictor. None of the three 
models had a significantly different AUC than that of advanced age alone for identifying 
patients who developed VTE (p=0.284; Table 3). Calibration plots showed significant 
miscalibration for Caprini score and advanced age alone (Supplementary Figure 1). 
However, probabilistic precision of the prediction was close for all models, with a Brier 
score of 0.0175, 0.0176, 0.0176 and 0.0176 for Padua, Caprini, IMPROVE and advanced 
age, respectively.
Secondary analysis: Threshold analysis 
The IMPROVE score and advanced age classified the highest proportion of patients as 
low-risk (Table 4). Based on the Padua, Caprini, IMPROVE (intermediate-high and high) 
scores or advanced age in low-risk patients, VTE occurred in 0.6%, 0.5%, 1.0%, 1.6% 
and 1.2 %, respectively (Table 4). In high-risk patients, VTE occurred in 2.2%, 1.9%, 
2.5%, 3.0% and 2.3%, respectively for Padua, Caprini, IMPROVE (intermediate-high and 
high) scores and advanced age (Table 4). Global performances assessed with the 
Youden Index were poor for the three RAMs and for advanced age, all below 0.25. 
Temporal trends for each model according to their reported threshold are depicted in 
Figure 3. 
Sensitivity analyses
After exclusion of patients who received anticoagulant prophylaxis during their hospital 
stay (n=6,764) in a first sensitivity analysis, the AUC of predicting VTE was 0.66 (95% CI, 
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When considering only objectively confirmed VTE as primary outcome (n=137), the AUC 
was 0.66 (95% CI 0.62-0.70) for the Padua score, 0.61 (95% CI 0.57-0.65) for the Caprini 
score, 0.65 (95% CI 0.61-0.69) for the IMPROVE score, and 0.59 (95% CI 0.54-0.63) for 
advanced age (p=0.126 for difference across AUCs).
After exclusion of distal DVT as part of the primary outcome, the AUC was 0.65 (95% CI, 
0.62-0.68) for the Padua score, 0.60 (95% CI, 0.57-0.64) for the Caprini score, 0.63 (95% 
CI, 0.60-0.66] for the IMPROVE score, and 0.62 (95% CI, 0.59-0.65) for advanced age 
(p=0.195 for difference across AUCs).
Overall, 8,198 patients had available values for BMI. Of those 126 (1.5%) experienced 
symptomatic VTE. Considering only these patients with BMI values, the AUC was 0.61 
(95% CI, 0.57-0.66) for the Padua score, 0.61 [0.56-0.65] for the Caprini score, 0.66 
[0.62-0.70] for the IMPROVE score, and 0.59 [0.54-0.63] for advanced age (p=0.100 for 
difference across AUCs).
Discussion 
Our study provides new insights on the prediction of VTE in medically ill admitted 
patients, by directly comparing Padua, Caprini and IMPROVE scores, with advanced age 
as a stand-alone predictor in a very large cohort of prospectively enrolled patients. 
Discriminant ability appears to be low for all RAMs (AUC ranging from 60 to 65%) and 
none of them are able to perform better than advanced age alone, simple and readily 
available information. The extent of these observations is restricted to medical patients 
not admitted to the ICU and limited by the availability of the body mass index, required for 
some RAMs. 
Most recent guideline recommendations for VTE prophylaxis in hospitalized medical 
patients are based on  risk stratification using clinical prediction rules.[8,9] Several RAMs 
have been proposed, but none of them are strongly validated. Padua and Caprini scores 
were built by expert consensus, whereas the IMPROVE score was obtained from 
multivariate logistic regression derivation/validation studies.[10–12] In 2012, the 
American College of Chest Physicians (ACCP) guidelines based their recommendations 
on the Padua score, because at the time the guidelines were written, the Padua score 
represented the “best available basis for judging hospitalized patients’ risk”.[8] However, 
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suboptimal validation as limitations of this risk model. The Padua score was prospectively 
validated in a cohort study which included 1,180 patients admitted to an internal medicine 
ward. The rate of VTE was 3.1% at three-months. In this study, all patients underwent 
systematic screening for VTE at 3-months. Unexplained sudden deaths were not 
considered as VTE events. The event rate in the low risk group (Padua score <4) was 
0.3% during the three-months follow-up.[10]  A prospective multicentre cohort of 1,478 
medical inpatients, with a 2.3% incidence of VTE, showed conflicting results. Among the 
764 low risk patients according to the Padua score, 1.1% had symptomatic VTE event at 
three months.[20] Other retrospective studies reported an AUC of 0.62 or less.[21–23] 
The Caprini score was first evaluated and validated to predict VTE in surgical patients. A 
retrospective cohort validated the Caprini score in medical patients and reported an AUC 
of 0.63.[22] Better performances for the Padua and Caprini scores were reported, but the 
case control design of these studies created higher prevalence resulting in increased 
sensitivity and thus, biased performance estimates.[24–26] The IMPROVE score was 
derived using regression analysis in a mixed pro- and retrospective cohort of medical 
inpatients. As for the Padua and Caprini scores, performances in external validation 
studies vary widely, with AUC between 0.56 and 0.77.[27–30] It is not uncommon for risk 
scores in general to be over-optimistic in the dataset they were derived from. In the 
recent MARINER trial comparing rivaroxaban 10 mg daily to placebo for extended 
thromboprophylaxis, a modified IMPROVE score incorporating D-dimer levels was used 
to identify patients at high risk of VTE during the three-month follow-up period.[31] The 
addition of the D-dimer levels was shown to slightly improve the discriminating ability of 
the score.[30] In spite of this, the score failed to identify a population at high risk with only 
66 out of 6,012 patients (1.2%) in the placebo arm developing VTE during follow-up. 62% 
of primary outcomes were unexplained sudden deaths, leaving only 22 (0.4%) objectively 
confirmed symptomatic VTE events in patients treated with placebo. In summary, our 
results support previous studies indicating poor discriminant ability of the three scores in 
external validation studies. More recently, a retrospective application of the IMPROVE 
score combined with a D-dimer test was able to identify a subgroup of patients with a 
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Age is one of the major determinants of VTE and is taken into account in all risk 
prediction models for medically ill inpatients.[10–12] As a consequence, recent clinical 
trials on VTE prophylaxis used advanced age as one of their major selection 
criteria.[31,33] Our results suggest that age can be used as a single predictor, sufficient 
to classify patients as having a low or high risk of VTE. Its prediction performance is 
similar to all risk prediction models that we evaluated. Moreover, a strategy based on age 
alone is easily implementable in everyday clinical practice. Above the age of 70, the risk 
of VTE exceeded 2% at 3-months, but the higher the age, the higher the risk of VTE. 
Advanced age could easily be used in a quantitative way to gauge the risk of VTE.
Some subgroups of patients might benefit from dedicated risk assessment tools, such as 
cancer patients or those with a prior history of venous thromboembolism. These 
subgroups respectively represented 12.3% and 6.2% of the overall population. That is the 
same for patients known to have elevated D-dimer levels.[34] The risk of VTE was shown 
to gradually increase for each increment of 250µg/L of D-dimer. It is also interesting to 
note that the rate of anticoagulant prophylaxis was higher in patients who developed 
VTE. This might be mainly due to the ability of physicians to identify high-risk patients 
and select them for anticoagulant prophylaxis. However, another hypothesis is that it 
might be the consequence of a suboptimal efficacy of anticoagulant prophylaxis.    
Strengths and limitations
To our knowledge, the PREVENU study is the largest cohort of consecutively and 
prospectively followed medical inpatients.[14] Some larger registries of VTE patients are 
available, but these retrospective registries faced challenges for the calculation of risk 
scores.[27,29,35] Moreover, the case-control design artificially increases the prevalence 
of the disease, modifying the tests properties.[27,29] The prospective and consecutive 
inclusion of patients in the PREVENU study ensures high data quality. Our main outcome 
was symptomatic VTE, and all events were adjudicated by an independent committee. In 
contrast, most randomised control trials of thromboprophylaxis for medical inpatients 
used systematic screening of asymptomatic VTE.[33] The clinical implications and the 
need for treatment of asymptomatic VTE remain controversial, especially for distal 
VTE.[16] Excluding symptomatic below the knee DVT did not modify our conclusion. 
Nevertheless, our study has limitations. Firstly, as a substitute of bed confinement 
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follow-up. However, we do not expect that this limitation explains the observed low 
performances of the scores. Quite the contrary, the anticipated duration of bed 
confinement appears arduous to predict at admission. The effective hospital length of 
stay provides a much more precise estimate of the exposure to the risk of VTE. 
Moreover, there is a wide variability in the definition of bed confinement between scores, 
making it difficult to implement in clinical practice and complicating its interpretation in 
retrospective studies. It is to be recalled that patients admitted in the ICU were not 
included in the study, not allowing to conclude on this specific subgroup. Patients were 
eligible to the study if still present beyond 48hours from admission. So, patients admitted 
in medical ward presenting early deterioration and transferred to the ICU were not 
recruited. Secondly, body mass index was not always available, leading to perform 
random forest multiple imputation. BMI was part of Padua and Caprini risk scores which 
may represent a cause of miscalibration. Nevertheless, the sensitivity analysis excluding 
patients with unknown body mass index did not alter our results. The absence of ICU 
stay and BMI might have especially decreased the IMPROVE score discrimination 
abilities, as both a required to assess this score. Thirdly, nearly half of the main outcome 
events were sudden death without objectively confirmed cause. As necropsy was not 
regularly performed, some events might not have been the direct consequence of a 
pulmonary embolism. Including those patients in the primary outcome constituted a more 
sensitive approach. Furthermore, a sensitivity analysis having only consider objectively 
confirmed VTE did not alter the results. Lastly, around half of patients received 
thromboprophylaxis with a wide panel of different regimens depending on physicians’ 
clinical practice. This may have influenced the occurrence of venous thromboembolism. 
However, our results were unchanged when restricting the analysis to patients who did 
not receive anticoagulant prophylaxis during their stay.
Conclusion
In this cohort of patients hospitalised for an acute medical illness, the Padua, Caprini and 
IMPROVE VTE RAMs have poor discrimination ability to identify patients at risk of VTE 
and do not offer a better prediction than advanced age alone. These results do not apply 
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Table 1. Covariates in the Padua, Caprini and IMPROVE scores, method of collection and 
availability. CCU: critical care unit, ICU: intensive care unit, VTE: venous thromboembolism.







>60: +1 Prospectively collected none
Body Mass Index ≥30: +1 >25: +1 NA Prospectively collected 44%
Medical history
     Cancer +3 +2 +2 Prospectively collected none
     Previous VTE +3 +3 +3 Prospectively collected none
     Known thrombophilia +3
+3 for 
each
+2 Prospectively collected none
     Family history VTE NA +3 NA Not collected Not collected
     Unexplained abortion NA +1 NA Not collected Not collected
     Varicose veins NA +1 NA Prospectively collected <1‰
     Inflammatory bowel 
disease
NA +1 NA Prospectively collected <1‰
     Heparin induced 
thrombocytopenia
NA +3 NA
Collected from serious 
adverse events
none
Recent condition (<1 month)
     Stroke NA +5 NA
     Spinal cord injury NA +5 NA
Named “neurological 
condition with lower 
limb paralysis”
none
     Surgery +1 NA Prospectively collected <1‰
     Trauma
+2
NA NA Prospectively collected none
     Peripartum NA +1 NA Prospectively collected none
     Heart failure NA +1 NA Prospectively collected none
     Sepsis NA +1 NA Prospectively collected none
     Pneumonia NA +1 NA












Imputed with length of 
hospital stay minus 
one day
none
     Heart failure +1 NA Prospectively collected none
     Respiratory failure
+1
+1 NA Prospectively collected none
     Myocardial infarction +1 NA Prospectively collected none
     Stroke NA Prospectively collected none
     Lower limb paralysis
+1
+5
+2 Prospectively collected none
     Acute infection +1 NA Prospectively collected none
     Rheumatologic disease
+1
NA NA Prospectively collected none
     Hormonal treatment +1 +1 NA Prospectively collected <1%
     Swollen legs NA +1 NA Not collected Not collected
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     Type of surgery NA +1/+2 /+5 NA Excluded* none
     Major bone fracture NA +5 NA Prospectively collected none
     Plaster cast NA +2 NA Prospectively collected none
     ICU/CCU stay NA NA +1 Not recruited Not collected
* Except surgery under local analgesia, considered +1 point
NA: Not applicable, items are not part of the risk assessment model.
Figure 1. Flow Chart. 
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Table 2. Characteristics of studied patients
Data are in median [interquartile range] or % [95% confidence interval]
Characteristics Values
Age, years 0.73 [59-83]
Sex Male 49.9% [49.1-50.7]
Body mass index, kg/m2 25.5 (±4.75)
Hospital length of stay, days .007 [4-13]
Medical history
   Venous thromboembolism 06.2% [5.8-6.6]
   Cancer 12.3% [11.8-12.8]
   Myeloma 01.0% [0.8-1.1%]
   Nephrotic syndrome 00.8% [0.7-1.0]
   Thrombophilia 00.2% [0.1-0.2]
Recent condition (<1 month)
   Stroke 09.9% [9.4-10.4]
   Heart failure 08.0% [7.6-8.5]
   Respiratory failure 11.9% [11.4-12.4]
   Acute myocardial infarction 02.9% [2.6-3.2]
Aspirin treatment 25.4% [24.7-26.2]
Estrogenic treatment 00.3% [0.3-0.5]
Clinical venous insufficiency 08.0% [7.6-8.5]
Bone fracture or cast of lower leg 00.6% [0.5-0.7]
Current lower limb paralysis   0.6% [0.4-0.7]
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Table 3. Area Under the ROC curve according the different models. Data is in % [95% 
confidence interval]. p-values are the probability of at least one of the three AUC of the risk 
assessment models greater than the AUC of advanced age alone.
Models All patients p No anticoagulant p
Age 0.61 [0.58-0.64] -ref- 0.66 [0.62-0.70] -ref-
Padua 0.64 [0.61-0.67] 0.66 [0.62-0.71]
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Table 4. Distribution on patients according the different scores.
Models Proportion in low 
risk
VTE in low risk
(1-NPV)








n (%) % [95% CI] % [95% CI] % [95% CI] % [95% CI] % [95% CI]
Padua ≥ 4 3,706 (25.3) 0.59 [0.39-0.90] 2.20 [1.93-2.49] 91.6 [87.6-94.7] 25.6 [24.9-26.3] 0.17 [0.12-0.21]
Caprini ≥ 3 1,086 (7.4) 0.46 [0.20-1.07] 1.90 [1.68-2.14] 98.1 [95.6-99.4] 7.5 [7.1-8.0] 0.06 [0.03-0.07]
IMPROVE ≥ 2 6,848 (46.7) 1.01 [0.80-1.27] 2.48 [2.16-2.85] 73.8 [68.0-79.0] 47.1 [46.3-47.9] 0.21 [0.14-0.27]
IMPROVE ≥ 4 12,509 (85.3) 1.58 [1.38-1.82] 3.02 [2.38-3.83] 24.7 [19.6-30.4] 85.5 [84.9-86.1] 0.10 [0.05-0.16]
Age ≥ 70 6,255 (42.7) 1.18 [0.94-1.48] 2.25 [1.95-2.59] 71.9 [66.0-77.2] 42.9 [42.1-43.8] 0.15 [0.08-0.21]
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Figure 2. ROC curves of performances of models and age (continuous) in overall cohort (A) and in the 
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Figure 3. Kaplan-Meier plot for the occurrence of symptomatic venous thromboembolism (VTE) 
over 90-days in low vs high-risk patients according to the Padua score (A), the IMPROVE score 
(B) and the Caprini score (C) compared to advanced age. Advanced age thresholds were 
adjusted so than the probability of VTE was equal in the low risk group at day 90 of follow-up. 
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